To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307
A Dose-escalation, Single-arm, Open-Label, Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307, Autologous Glypican 3 Targeted Chimeric Antigen Receptor T Cell Therapy in Patients With GPC3 Positive Advanced Hepatocellular Carcinoma Who Have Failed Standard Therapy
Sponsor: Eutilex
Listed as NCT05783570, this PHASE1 trial focuses on Advanced Hepatocellular Carcinoma and remains actively recruiting participants. Sponsored by Eutilex, it has been updated 6 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2023 — Apr 2024 [monthly]
Not Yet Recruiting PHASE1
▶ Show 1 earlier version
-
Apr 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eutilex
For direct contact, visit the study record on ClinicalTrials.gov .